Loading clinical trials...

Guideline Directed Medical Therapy (GDMT) Optimization and Adherence Longitudinal Study for Heart Failure. | Clinical Trials | Clareo Health

COMPLETED

Guideline Directed Medical Therapy (GDMT) Optimization and Adherence Longitudinal Study for Heart Failure.

Guideline Directed Medical Therapy (GDMT) Optimization and Adherence Longitudinal Study for Heart Failure. (GOALS-HF)

NCT05906745•Tricog Health Inc

View on ClinicalTrials.gov

Summary

A multicenter, non-randomized prospective longitudinal study to evaluate the feasibility of Tricog's Remote platform for Guideline Directed Medical Therapy (GDMT) titration and remote patient monitoring among patients with Heart Failure.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥ 18 years
•2. Recent hospitalization (within 4 weeks of enrollment) for HF with IV diuretic use
•3. Echocardiographic data with EF measurements available in the last 6 months and after HF diagnosis
•4. Established outpatient care at the participating sites
•5. Eligible to receive at least 2 of the 4 GDMT classes (ACEi/ARB/ARNi, Beta-blockers, MRA, and SGLT2i) for HFrEF and HFmrEF and at least one of the three (ARB/ARNI, MRA, SGLT2i) for HFpEF
•6. Not on Target GDMT for all the eligible GDMT classes
•7. \>12 months of expected survival
•8. Comfortable with spoken and written English communication
•9. Access to Apple Watch-compatible iPhone

Exclusion Criteria

•1. Under consideration for or recipient of advanced heart failure therapies (LVAD, Transplant)
•2. Current or anticipated use of home intravenous inotrope therapy.
•3. Unwilling or unable to perform all study related procedures (wear watch, take measurements and maintain daily logs)
•4. Post-discharge placement in nursing, rehabilitation, or long-term care facility
•5. Planned (within next 6 months) surgery
•6. Inability to provide written consent

Locations (4)

Duke University Medical Center

Durham, North Carolina, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Manipal Hospital

Bengaluru, Karnataka, India

Sakra World Hospital

Bengaluru, Karnataka, India

Key Dates

Start Date

July 21, 2023

Primary Completion Date

September 27, 2024

Completion Date

September 27, 2024

Last Updated

February 19, 2025

Enrollment

ACTUAL participants

Conditions

Heart Failure

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Guideline Directed Medical Therapy (GDMT) Optimization and Adherence Longitudinal Study for Heart Failure.

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation